This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics Future Growth

Future criteria checks 5/6

Calliditas Therapeutics is forecast to grow earnings and revenue by 55.5% and 34.3% per annum respectively.

Key information

55.5%

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	21.6%
Revenue growth rate	34.3%
Future return on equity	n/a
Analyst coverage	Good
Last updated	11 Oct 2024

Recent future growth updates

No updates

Recent updates

No updates

Earnings and Revenue Growth Forecasts

MUN:LC8A - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	4,963	1,451	4,590	4,617	4
12/31/2025	3,274	836	1,703	1,735	6
12/31/2024	2,021	-68	358	374	6
6/30/2024	1,601	-480	-258	-245	N/A
3/31/2024	1,311	-525	-414	-401	N/A
12/31/2023	1,207	-466	-447	-435	N/A
9/30/2023	1,184	-451	-230	-227	N/A
6/30/2023	1,150	-292	-292	-290	N/A
3/31/2023	944	-393	-354	-352	N/A
12/31/2022	803	-412	-314	-311	N/A
9/30/2022	405	-628	-724	-703	N/A
6/30/2022	343	-608	-634	-611	N/A
3/31/2022	279	-576	-541	-519	N/A
12/31/2021	229	-500	-484	-462	N/A
9/30/2021	199	-452	-422	-420	N/A
6/30/2021	0	-600	-490	-490	N/A
3/31/2021	0	-501	-425	-425	N/A
12/31/2020	1	-433	-309	-309	N/A
9/30/2020	47	-286	-233	-235	N/A
6/30/2020	47	-198	-64	-48	N/A
3/31/2020	185	-54	-57	-40	N/A
12/31/2019	185	-33	-87	-71	N/A
9/30/2019	138	-54	-86	-68	N/A
6/30/2019	138	-35	-166	-166	N/A
3/31/2019	N/A	-136	-144	-144	N/A
12/31/2018	N/A	-132	-128	-128	N/A
9/30/2018	N/A	-128	-112	-112	N/A
6/30/2018	N/A	-115	-114	-114	N/A
3/31/2018	N/A	-113	N/A	-89	N/A
12/31/2017	N/A	-87	N/A	-68	N/A
12/31/2016	N/A	-57	N/A	-55	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LC8A is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).

Earnings vs Market: LC8A is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LC8A is expected to become profitable in the next 3 years.

Revenue vs Market: LC8A's revenue (34.3% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: LC8A's revenue (34.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LC8A's Return on Equity is forecast to be high in 3 years time